Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Antisense Therapeutics, Cortendo deal

May 25, 2015 7:00 AM UTC

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties. Cortendo will fund manufacturing, regulatory and developmental costs for the second-generation antisense inhibitor of growth hormone receptor (GHr), which is in Phase II testing to treat acromegaly. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article